NCM
RGNX icon

Numina Capital Management’s Regenxbio RGNX Stock Holding History

Numina Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-185,471
Closed -$3.44M – 40
2016
Q4 		$3.44M Buy
+185,471
New +$3.54M 0.42% 34

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Numina Capital Management's RGNX Position: Q1 2017 in Review

Numina Capital Management sold out of Regenxbio (RGNX) in Q1 2017, closing a stake of 185,471 shares — an estimated $3.44M sold.

Numina Capital Management first reported a position in RGNX in Q4 2016 and held it in 1 quarter. The position peaked at $3.44M in Q4 2016. 85 funds tracked by Wall St. Rank hold RGNX as of Q1 2017.

  • Numina Capital Management reported no remaining Regenxbio position as of Q1 2017 after selling out during the quarter.
  • Numina Capital Management sold 185,471 Regenxbio shares in Q1 2017, an estimated $3.44M.
  • Numina Capital Management first reported a position in Regenxbio in Q4 2016 and held it in 1 quarter.
  • Numina Capital Management's Regenxbio position peaked at $3.44M in Q4 2016.
  • 85 funds tracked by Wall St. Rank held Regenxbio as of Q1 2017.

Based on Numina Capital Management's 13F filing for Q1 2017, filed 15 May 2017.